delmadinone and Prostatic-Hyperplasia

A multicentre randomised clinical trial was performed to compare the therapeutic potential of osaterone acetate with that of delmadinone acetate in the treatment of benign prostatic hyperplasia in dogs. The osaterone was administered orally at 0.25 mg/kg bodyweight once a day for seven days to 73 dogs. The delmadinone was administered by a single intramuscular or subcutaneous injection at 3 mg/kg bodyweight to 69 dogs. During the 180-day trial, the dogs were monitored five times for their clinical signs and prostate volume. The two drugs were similarly effective in reducing the clinical signs and inducing complete clinical remission, and both induced a similar level of minor, mostly transitory adverse effects. Osaterone reduced the volume of the prostate glands of the dogs significantly more quickly than delmadinone.

Topics: Androgen Antagonists; Animals; Chlormadinone Acetate; Dog Diseases; Dogs; Drug Administration Schedule; Male; Prostatic Hyperplasia

A two year old male Labrador Retriever was treated with delmadinone acetate because of benign prostatic hyperplasia. Four days after the injection the dog showed gastrointestinal signs and a progressive lethargy. In the hospital for small animals of the Justus-Liebig-University of Gießen an ACTH stimulation test was done and a secondary hypoadrenocorticism was diagnosed. The dog was treated with prednisolone in physiological dose for 14 weeks after the injection. The clinical symptoms stopped immediately. A new ACTH stimulation test some weeks later showed a completely normal adrenal function.. Ein zwei Jahre alter, unkastrierter Labrador Retriever Rüde wurde beim Haustierarzt wegen einer benignen Prostatahyperplasie mit Delmadinonacetat behandelt. Vier Tage nach der Injektion entwickelte der Rüde gastrointestinale Symptome und eine progressive Lethargie. In der Klinik für Kleintiere der Justus-Liebig-Universität Gießen wurde mittels ACTH-Stimulationstest ein sekundärer Hypoadrenokortizismus diagnostiziert. Der Rüde wurde bis zur 14. Woche nach der Injektion von Delmadinonacetat auf eine physiologische Dosis von Prednisolon gesetzt. Der klinische Zustand des Hundes besserte sich sofort nach Beginn der Therapie. Ein erneuter ACTH-Stimulationstest einige Wochen später zeigte eine komplette Rekonvaleszenz der Nebennierenfunktion.

Topics: Adrenal Insufficiency; Animals; Chlormadinone Acetate; Dog Diseases; Dogs; Glucocorticoids; Male; Prednisolone; Prostatic Hyperplasia; Treatment Outcome

To characterise the effects of delmadinone acetate on the pituitary-adrenal axis, glucose tolerance and growth hormone concentration in normal male dogs and dogs with benign prostatic hyperplasia.. A prospective study involving nine normal male dogs and seven with prostatic hyperplasia.. Delmadinone acetate was administered to six normal male dogs and seven dogs with benign prostatic hyperplasia at recommended dose rates (1.5 mg/kg subcutaneously at 0, 1 and 4 weeks). Three normal controls received saline at the same intervals. Blood concentrations of ACTH, cortisol, glucose, insulin and growth hormone were measured over 50 days. Intravenous glucose tolerance and ACTH response tests were performed before and after treatment in the nine normal animals.. A substantial suppression of basal and 2 h post-ACTH plasma cortisol secretion was demonstrated after one dose in all dogs given delmadinone acetate. Individual responses after the second and third administration varied between recovery in adrenal responsiveness to continued suppression. Plasma ACTH concentration was also diminished after one treatment. No effects were evident on glucose tolerance or serum growth hormone concentrations.. Delmadinone acetate causes adrenal suppression from inhibition of release of ACTH from the pituitary gland. Treated dogs may be at risk of developing signs of glucocorticoid insufficiency if subjected to stressful events during or after therapy. Neither glucose intolerance nor hypersomatotropism seems likely in male dogs given delmadinone acetate at the recommended dose rate, but the potential for excessive growth hormone secretion in treated bitches remains undetermined.

Topics: Adrenal Cortex; Adrenal Insufficiency; Adrenocorticotropic Hormone; Analysis of Variance; Animals; Blood Glucose; Chlormadinone Acetate; Contraceptive Agents; Dog Diseases; Dogs; Glucose Intolerance; Glucose Tolerance Test; Growth Hormone; Hydrocortisone; Insulin; Male; Pituitary-Adrenal System; Progestins; Prospective Studies; Prostatic Hyperplasia; Radioimmunoassay; Random Allocation